Dr Todd Michael Bauer speaks to ecancer about the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC).
He talks about an updated follow-up of a phase I/II study investigating MK-6482. Initially, he explains what the study was about. He then talks about the methodology used in this study and then moves on to discuss the key results obtained from this study.
In the end, he talks about the future impact the results from this study can have on the treatment of advanced clear renal cell cancer.